Making large-volume subcutaneous drug delivery possible with SHL Medical’s Magnitude

In subcutaneous drug delivery, large-volume injections are becoming increasingly relevant as biologics continue to evolve, creating new requirements for device performance, usability, and manufacturing readiness. In a newly published interview with ONdrugDelivery, Vince Masciopinto, Customer Solutions Director at SHL Medical, discusses the evolution of the Maggie platform into Magnitude and shares insights into the considerations driving the next generation of large-volume drug delivery systems.

The interview explores how cartridge-based autoinjector design, SHL Medical's proprietary Needle Isolation Technology (NIT), and fluid-path optimization can help address the challenges associated with delivering volumes in the 2.0-5.0 mL range. It also examines the importance of maintaining a compact device form factor, supporting user needs, and enabling flexibility without requiring changes to the primary container.

Read the full interview, When More Matters - Advancing Large-Volume Drug Delivery with Magnitude, to learn how SHL Medical is helping pharmaceutical partners navigate the complexities of large-volume combination product development and commercialization.